Full text is available at the source.
Abstract
Audiovestibular adverse-event reporting patterns among glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were analyzed using the US Food and Drug Administration Adverse Event Monitoring System.
- Reporting patterns were characterized for different GLP-1 RAs.
- Comparison of adverse events may reveal variability among GLP-1 RAs.
- The analysis focuses on audiovestibular events, which include hearing and balance issues.
- Findings could inform clinicians about potential risks associated with GLP-1 RAs.
Simplified